Zobrazeno 1 - 10
of 13
pro vyhledávání: '"Melinda Yushak"'
Autor:
Brian Burns, Elizabeth Evans, Ragini Kudchadkar, Crystal Mallow, Christine Reilly, Maurice Zauderer, Gregory B Lesinski, Keith A Delman, Chrystal M Paulos, Brian Olson, Terrence Fisher, Jayden Kim, Michael C Lowe, Ayana T Ruffin, Jacklyn Hammons, Agnes Harutyunyan, Melinda Yushak, Ali Mokhtari, Douglas Parker
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 11, Iss Suppl 1 (2023)
Externí odkaz:
https://doaj.org/article/8b6f56ca06554f4e801dde08a7b6b1a3
Autor:
Hannah M. Knochelmann, Michael Brandon Ware, Aditya Rali, Susanne Linderman, Jessica G. Shantha, David H. Lawson, Melinda Yushak, Robert Swerlick, Chrystal M. Paulos, Steven Yeh, Ragini Kudchadkar
Publikováno v:
Frontiers in Oncology, Vol 12 (2022)
Autoimmune toxicities, while common following treatment with cancer immunotherapies, are not well-characterized in patients treated with BRAF/MEK inhibitors. Emerging data suggest that autoimmune effects may be linked with superior responses to both
Externí odkaz:
https://doaj.org/article/5682dd66a7c94c14983544e2aef025d4
Autor:
Robert H.I. Andtbacka, Yan Wang, Robert H. Pierce, Jean S. Campbell, Melinda Yushak, Mohammed Milhem, Merrick Ross, Katie Niland, Robert D. Arbeit, Sudha Parasuraman, Kris Bickley, Cecilia CS Yeung, Lauri D. Aicher, Kimberly S. Smythe, Lu Gan
Publikováno v:
Cancer Research Communications. 2:904-913
Purpose: Mavorixafor is an oral, selective inhibitor of the CXCR4 chemokine receptor that modulates immune cell trafficking. A biomarker-driven phase Ib study (NCT02823405) was conducted in 16 patients with melanoma to investigate the hypothesis that
Autor:
Lu Gan, Kimberly S. Smythe, Lauri D. Aicher, Cecilia CS Yeung, Kris Bickley, Sudha Parasuraman, Robert D. Arbeit, Katie Niland, Merrick Ross, Mohammed Milhem, Melinda Yushak, Jean S. Campbell, Robert H. Pierce, Yan Wang, Robert H.I. Andtbacka
Antibody panels used for mIF analyses.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3d2a1af716f0bd76c6e9fa7b043dbd23
https://doi.org/10.1158/2767-9764.22545773.v1
https://doi.org/10.1158/2767-9764.22545773.v1
Autor:
Lu Gan, Kimberly S. Smythe, Lauri D. Aicher, Cecilia CS Yeung, Kris Bickley, Sudha Parasuraman, Robert D. Arbeit, Katie Niland, Merrick Ross, Mohammed Milhem, Melinda Yushak, Jean S. Campbell, Robert H. Pierce, Yan Wang, Robert H.I. Andtbacka
Serum cytokine and chemokine changes at the end of the 3-week monotherapy period compared to baseline.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::9c5098d1822b7b01f14f78eb4c3a72ba
https://doi.org/10.1158/2767-9764.22545770.v1
https://doi.org/10.1158/2767-9764.22545770.v1
Autor:
Lu Gan, Kimberly S. Smythe, Lauri D. Aicher, Cecilia CS Yeung, Kris Bickley, Sudha Parasuraman, Robert D. Arbeit, Katie Niland, Merrick Ross, Mohammed Milhem, Melinda Yushak, Jean S. Campbell, Robert H. Pierce, Yan Wang, Robert H.I. Andtbacka
Purpose:Mavorixafor is an oral, selective inhibitor of the CXCR4 chemokine receptor that modulates immune cell trafficking. A biomarker-driven phase Ib study (NCT02823405) was conducted in 16 patients with melanoma to investigate the hypothesis that
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::412d1a88bdb6c622134f34d6dd3e332d
https://doi.org/10.1158/2767-9764.c.6551033.v1
https://doi.org/10.1158/2767-9764.c.6551033.v1
Autor:
Lu Gan, Kimberly S. Smythe, Lauri D. Aicher, Cecilia CS Yeung, Kris Bickley, Sudha Parasuraman, Robert D. Arbeit, Katie Niland, Merrick Ross, Mohammed Milhem, Melinda Yushak, Jean S. Campbell, Robert H. Pierce, Yan Wang, Robert H.I. Andtbacka
Shared TCR TIL sequences taken from tumor biopsy of patient #5 at various timepoints.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::00a79627298ef8dc5b78551cef478a86
https://doi.org/10.1158/2767-9764.22545779.v1
https://doi.org/10.1158/2767-9764.22545779.v1
Autor:
Lu Gan, Kimberly S. Smythe, Lauri D. Aicher, Cecilia CS Yeung, Kris Bickley, Sudha Parasuraman, Robert D. Arbeit, Katie Niland, Merrick Ross, Mohammed Milhem, Melinda Yushak, Jean S. Campbell, Robert H. Pierce, Yan Wang, Robert H.I. Andtbacka
Depiction of T cell clone mobilization from peripheral blood to melanoma site on day 1 and at EOT.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0e18f10426dc9934d3fce1d6e4d95278
https://doi.org/10.1158/2767-9764.22545776
https://doi.org/10.1158/2767-9764.22545776
Autor:
Brian Olson, Crystal Mallow, Christine Reilly, Jacklyn Hammons, Jayden Kim, Brian Burns, Agnes Harutyunyan, Elizabeth Evans, Terrence Fisher, Maurice Zauderer, Keith Delman, Melinda Yushak, Ali Mokhtari, Douglas Parker, Chrystal Paulos, Gregory Lesinski, Michael Lowe
Publikováno v:
Regular and Young Investigator Award Abstracts.
Autor:
Hannah M. Knochelmann, Michael Brandon Ware, Adiiya Rali, Susanne Lindermann, Jessica G. Shantha, David H. Lawson, Melinda Yushak, Robert Swerlicke, Chrystal M. Paulos, Steven Yeh, Ragini Kudchadkars
Publikováno v:
Kompass Dermatologie. 10:154-161
Autoimmuntoxizitäten, die nach der Behandlung mit Krebsimmuntherapien häufig auftreten, sind bei Patienten, die mit BRAF/MEK-Inhibitoren behandelt werden, nicht gut charakterisiert. Neuere Daten deuten darauf hin, dass Autoimmuneffekte mit einem ü